Skip to main content
OpenTrials
Completed

NCT Number: NCT03752866

CONFIDENCE Registry to Assess Safety and Performance of Portico System to Treat Patients With Severe Aortic Stenosis.

The purpose of this clinical investigation is to characterize the procedural safety and device performance of transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in patients with symptomatic degenerative aortic stenosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Heart Care Partners- Wesley Hospital, Woolloongabba, Queensland, Australia

Loading trial locations.

About this study

The CONFIDENCE registry study will be conducting as a prospective, non-randomized, observational, single-arm, multi-center study.

Approximately 1000 subjects with severe symptomatic (NYHA class ≥ II) aortic stenosis (AS), will undergo Portico™ Transcatheter Aortic Heart Valve implantation.

The subject data will be collected at baseline, index procedure, pre- discharge, 30 days and 12 months from the index procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who are ≥18 years of age or legal age in host country and have been identified as a candidate for a Portico™ valve implant
  • Subjects who have been informed of the nature of the study, agree to its provisions and have provided written informed consent as approved by the Ethics Committee (EC) of the respective clinical center

Exclusion criteria

  • Have sepsis, including active endocarditis
  • Have any evidence of left ventricular or atrial thrombus
  • Have vascular conditions (i.e. caliber, stenosis, tortuosity, or severe calcification) that make insertion and endovascular access to the aortic valve improbable
  • Have a non-calcified aortic annulus
  • Have congenital bicuspid or unicuspid leaflet configuration
  • Are unable to tolerate antiplatelet/anticoagulant therapy
  • Are pregnant at the time of signing informed consent
  • Are currently participating in a drug or device study that may impact the registry (unless prior sponsor approval for co-enrollment is granted)

Treatment and study plan

Portico™ Valve, Portico Delivery System(s) and Loading System(s)

Device

Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.

Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)

Device

Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.

Primary outcomes

  1. Cardiovascular Mortality

    Time frame: 30 days from the index procedure

    Death due to proximate cardiac cause, non-coronary vascular conditions, procedure-related deaths, valve-related deaths, sudden or unwitnessed death and unknown cause.

Secondary outcomes

  1. Number of Subjects With Myocardial Infarction

    Time frame: At 30 days

  2. Number of Subjects With Stroke

    Time frame: At 30 days

  3. Number of Subjects With Bleeding Events

    Time frame: At 30 days

  4. Number of Subjects With Acute Kidney Injury

    Time frame: At 30 days

    The increase in creatinine must occur within 48 hours.

    Stage 1: Increase in serum creatinine to 150% to 199% (1.5 to 1.99 X increase compared with baseline) or increase of greater than or equal to 0.3 mg/dL (26.4 mmol/L) or Urine output <0.5 mL/kg per hour for >6 but <12 hours.

    Stage 2: Increase in serum creatinine to 200% to 299% (2.0 to 2.99 X increase compared with baseline) or Urine output <0.5 mL/kg per hour for >12 but <24 hours.

    Stage 3: Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output <0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.

  5. Number of Subjects With Vascular Complications

    Time frame: At 30 days

  6. Number of Subjects With Annular Rupture

    Time frame: At 30 days

  7. Number of Subjects With Coronary Obstruction

    Time frame: At 30 days

  8. Number of Subjects Undergoing Conversion To Open Surgery

    Time frame: At 30 days

  9. Number Of Subjects Undergoing Transcatheter Valve-In-Valve Deployment

    Time frame: At 30 days

  10. Number Of Subjects With Valve Embolization

    Time frame: At 30 days

  11. Number Of Subjects Undergoing Naïve Permanent Pacemaker Insertion

    Time frame: At 30 days

  12. Vessel Diameter

    Time frame: At 30 days

  13. Introducer Sheath Used

    Time frame: At 30 days

    This is a yes or no question on the CRF. Sites report if the implanter used an introducer sheath (a special device used to facilitate introduction of the investigational device into the subjects vasculature).

  14. Implant Success

    Time frame: At 30 days

  15. Effective Orifice Area

    Time frame: At 30 days

    Effective orifice area is a measure of the working area of the implanted valve determined by echocardiograph.

  16. Aortic Valve Mean Gradient

    Time frame: At 30 days

    Aortic valve mean gradient is a measure of the pressure gradient across the aortic valve measured by echocardiograph.

  17. Number of Subjects With Paravalvular Leak (PVL)

    Time frame: At 30 days

  18. NYHA Classification

    Time frame: At 30 days

    NYHA Functional Classification is a system used to assess patient heart failure severity based on their limitations of physical activity. The four classes are described below:

    Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or shortness of breath.

    Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.

    Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.

    Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Subjects' NYHA Classification based on above criteria was assessed during follow up, and subjects were assigned to one of four classifications. Results are presented as percentage of all available subjects who were assigned each functional class (I-IV).

  19. EQ5D-3L Visual Analog Scale Value

    Time frame: At 30 days

    The EQ-5D-3L consists of EuroQoL 5 questions and 3 answering levels. The rating of questions includes: Level 1 no problems; Level 2 some problems; Level 3 Significant problems; Worst case is 15 points; and best case is 5 points using index. The Visual analogue scale VAS 0-100 where 0 is the worst imaginable health state and 100 the best imaginable health state."

  20. Kaplan-Meier Rate of All-cause Mortality

    Time frame: At 12 months

    Kaplan-Meier (KM) percentage of subjects who died. KM is a statistical method that attempts to account for other factors that may have reduced the number of subjects evaluable at a given time point.

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

CONtrolled Delivery For ImproveD outcomEs With cliNiCal Evidence

Important dates

Study start
2018
Primary completion
2021
Study completion
2022
First posted
Nov 26, 2018
Registry last updated
Oct 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.